We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Despite the FDA approving more than 99 percent of expanded access requests and offering emergency access authorization, a Senate committee chairman introduced legislation Tuesday that prohibits the FDA from interfering in the prescribing of investigational drugs to terminally ill patients. Read More
Clovis Oncology is stopping development of the lung cancer candidate rociletinib after the FDA warned the company of a potential complete response letter. Read More
The UK’s National Institute for Health and Care Excellence is backing cholesterol-lowering drugs from Sanofi and Amgen, provided the companies deliver discounted prices as promised. Read More
Sanofi is not bowing out of its efforts to buy Medivation, warning the company’s board that if it continues to brush off its overtures, it will pursue a hostile bid. Read More
The UK’s National Institute for Health and Care Excellence is recommending reimbursement of Novartis’ drug combination Mekinist and Tafinlar for treating unresectable or metastatic melanoma in patients with BRAF V600 mutations. Read More